Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease ...

According to TipRanks.com, Wright is a 5-star analyst with an average return of 14.5% and a 62.3% success rate. Wright covers the Healthcare sector, focusing on stocks such as BrightSpring Health ...

Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc.

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal ...

A Shanghai-based biopharmaceutical company commercializing rare kidney and autoimmune treatments across Greater China and ...

This comprehensive health news summary covers significant developments in the pharmaceutical and healthcare sectors.

June 2 (Reuters) - Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization ...

Travere Therapeutics (TVTX) stock is in focus as the company inks a licensing deal worth up to $1.1B with China’s Everest ...